Skip to main content
Premium Trial:

Request an Annual Quote

Reveo Joins Genomics X Prize Race; Aims to Sequence Genome, Proteome, and Epigenome 'for Pennies in Minutes'

NEW YORK  (GenomeWeb News) — Reveo has joined the Archon X Prize race for genome sequencing, the X Prize Foundation said today.
Reveo, base in Elmsford, NY, focuses on incubating, developing, and spinning out a variety of technology companies. Its offspring include technologies used in genomics, medical imaging, water desalinization, fuel cells, and optical communications.
According to the X Prize Foundation, the device Reveo will use in the Archon X race is the Omni Molecular Recognizer Application, which uses principles from semiconductor electronics and photonics "rather than indirect chemical methods to read the DNA sequence directly."
Reveo CEO Sadeg Faris said the biggest challenge his team will confront is fabricating nano-knife edges, which he said has not been done, at least according to published literature.
The company said it plans to use arrays of nano-knife-edge probes to "directly and non-destructively" read the human gene sequence.
The X Prize said Faris believes Reveo's concept can "accomplish and even surpass" the X Prize's requirements, and can "read an entire human genome, epigenome, and proteome simultaneously in minutes for pennies per genome."
Additional information about Reveo’s technology and research can be read here and here.
The X Prize launched the Archon X Prize last fall. It is offering $10 million to a team that can make a tool that can sequence 100 human genomes with 99.999-percent accuracy in 10 days for no more than $10,000 per genome.
Several industry players have already entered the quest, including VisiGen Biotechnologies, 454 Life Sciences, and the Foundation for Applied Molecular Evolution.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.